Japan’s Shionogi Says Its Covid Pill’s Sales May Hit $2 Billion

Oct.07 — Japanese drugmaker Shionogi & Co. Ltd. says sales of the Covid pill it is developing could reach $2 billion drug. The company expects to have late-stage trial data in Japan by December and plans to move quickly on filing for regulatory approval. Chief Executive Officer Isao Teshirogi spoke exclusively to Bloomberg’s Lisa Du.